Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Several possible studies

Story checked

GLP-1 pills are finally here. Here's the tradeoff nobody's advertising. (opens in a new tab)

health.yahoo.com · 2026-01-01

Short answerEvidenceSource

Short answer

Several possible studies

No confirmed study match.

Several papers could fit this story, but none could be confirmed as its source. The claims remain unverified.

21 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Several studies could be the source of this story.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Open claim evidence
3

Search result

Several studies could fit.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Source paper

Source layer

The 6 papers the story cites

Source study separated from background citations.

The research anchor for the report.

The literature search

21 candidate papers

Papers surfaced in our search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 17 more search results
Then inspect each claim

Evidence layer

Claim by claim

What the story asserts. With no source study, there is nothing to check these against.

Claim 1 of 9Not checkedThree GLP-1 pills are now on pharmacy shelves, giving people who have been hesitant about needles a new way to take these medications.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 2 of 9Not checkedGLP-1 pills may not be the best option for everyone, and the article says the decision between pills and injections depends on personality, lifestyle, and treatment goals.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 3 of 9Not checkedPills are taken daily, while injections are usually taken weekly.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 4 of 9Not checkedTwo of the three oral GLP-1 options require taking the pill on an empty stomach, while injections do not require fasting.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 5 of 9Not checkedThe article says GLP-1 pills generally have the same mild-to-moderate gastrointestinal side effects as injections, but a 2025 meta-analysis found pill users stopped treatment at nearly double the rate of shot users because of side effects (16% vs. 9%).View evidenceHide evidence

As stated16% vs. 9%

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 6 of 9Not checkedThe article says injections generally work better than pills for weight loss, although the gap depends on which drug is being compared.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 7 of 9Not checkedIn the article's comparison, the Wegovy pill produced about 13.6% weight loss in a 64-week trial, while the highest-dose oral GLP-1 Foundayo produced about 11.1% weight loss in a 72-week trial; tirzepatide injections produced about 20.2% weight loss over 72 weeks.View evidenceHide evidence

As stated13.6%, 11.1%, 20.2%

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 8 of 9Not checkedFor people with obesity-related complications, the article says an endocrinologist leans toward injections because more evidence supports them for specific conditions such as cardiovascular risk reduction and obstructive sleep apnea.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 9 of 9Not checkedA phase 3b trial in Nature Medicine is described as showing that people who switched from injectable semaglutide or tirzepatide to an oral GLP-1 retained most of their weight loss after one year, though they regained some weight.View evidenceHide evidence

As statedabout 79% and about 75% retained

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Finally, the search trail

Method layer

No single source study was found.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

Crossref, PubMed, Europe PMC · 21 candidate papers

Explore all search results